The use of creatine (including arginine creatine, a form of creatine) as a dietary supplement in muscular dystrophy has some scientific backing, though the evidence is modest and not universally conclusive. Creatine is a naturally occurring compound involved in energy production in muscle cells. The rationale for its use in muscular dystrophy, particularly Duchenne Muscular Dystrophy (DMD), is to help improve muscle strength and function, as muscle wasting is a hallmark of these conditions.

Several small, randomized controlled trials and meta-analyses have investigated creatine supplementation in boys with DMD and other neuromuscular disorders. Some studies report mild improvements in muscle strength and fat-free mass, and potential delays in the loss of ambulation. For instance, a 2013 Cochrane review concluded that creatine supplementation may have a small beneficial effect on muscle strength in muscular dystrophy, though the clinical significance is uncertain and larger, longer-term studies are needed. There is limited evidence specifically for arginine creatine, as most studies use creatine monohydrate.

Safety profiles in short-term use appear acceptable, but creatine is not a cure and does not halt disease progression. Current clinical guidelines do not universally recommend creatine, but it may be considered as an adjunct in some cases. Overall, there is some scientific rationale and preliminary evidence for its use, but it is not robustly validated.